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Edited by Lev KisselevAbstract Introns are present in some human pre-tRNAs. They
are spliced out during the maturation processes of pre-tRNAs in
a way that is irrelevant to their speciﬁc nucleotide sequences.
This unique characteristic of tRNA splicing can be used for
generation of small antisense RNAs by replacing the intron
sequences with corresponding antisense sequences. In this work,
the intron sequence of human pre-tRNAtyr gene was replaced
with a 20 bp antisense sequence targeted to the 50 coding region
of cyclin D1, a molecule that was over-expressed in many
malignant proliferating cells. Under the control of U6 SnRNA
promoter to further enhance transcription eﬃciency of the
modiﬁed pre-tRNAtyr gene and subsequent antisense generation,
the antisense RNA exhibited obvious suppression of cyclin D1
expression in H22 hepatoma cells. The growth of H22-
transplanted tumors in mice was signiﬁcantly inhibited when
treated with naked plasmid DNA harboring the cyclin D1
antisense RNA generating cassette. Such tumor growth inhibi-
tion might be due to apoptosis caused by reduced cyclin D1
expression as revealed by immunohistochemical analysis of
tumor samples.
 2004 Published by Elsevier B.V. on behalf of the Federation of
European Biochemical Societies.
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In eukaryotes, introns of tRNA precursors are small and
invariably interrupt the anticodon loop 1 base 30 to the
anticodon. During the maturation processes of tRNA pre-
cursors, which are best understood in yeasts, introns are re-
moved by a stepwise action of three enzymes: an endonuclease
that removes the intervening sequence, a ligase that joins the
two half molecules leaving a 20 phosphate at the splice junc-
tion, and a phosphotransferase that transfers the 20 phosphate
to NAD [1–3]. The endonuclease recognizes splice sites by
measuring the distance from the mature domain to the splice
sites. That means the speciﬁcity of cutting at both splice sites is
determined solely by the length of anticodon stem. Replace-
ment of the anticodon stem with equal length of poly(U)
yielded anticipated normal splicing [4]. However, the intron
itself is not completely passive in the recognition process. A* Corresponding author. Fax: +86-10-63815273.
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purine in the intron was reported to be necessary to position
the 30 splice site [5]. Whether a speciﬁc artiﬁcial intron in the
place of the native intron can be removed correctly has to be
determined experimentally. The endonuclease associates with
membranes in yeast [6]. Among its four subunits (Sen54p,
Sen2p, Sen34p and Sen15p), the Sen2p subunit contains a
potential transmembrane sequence. It was believed that en-
donuclease located in the nuclear membrane through anchor-
ing of Sen2p [7]. So splicing of tRNA was speculated to occur
near the inner nuclear membrane and might be coupled to
tRNA export [3]. However, a recent study showed that the
majority of Sen2p, Sen54p and the endonuclease activity are
not localized in the nucleus, but on the mitochondrial surface.
The endonuclease is peripherally associated with the cytosolic
surface of the outer mitochondrial membrane. Thus, it was
proposed that tRNA splicing mainly occurs on the mito-
chondrial surface in yeast [8]. Nevertheless, the human coun-
terpart of yeast endonuclease complex was located in the
nucleus [9], which, together with the fact that human intron-
containing tRNAtyr gene can be spliced correctly by Hela cell
nuclear extract [10], implies that human pre-tRNA splicing
occurs in nucleus. The fate of excised introns is rarely de-
scribed, but they exhibited good stability in yeast, which make
them easily detectable in Northern blot analyses [11]. As de-
scribed above, splicing of pre-tRNAs exhibited special prop-
erties that the speciﬁc intron sequences have little eﬀect on
correct splicing and the removed introns are stable, which
make it possible to utilize pre-tRNA splicing machineries to
generate small antisense RNA for gene silencing. By replacing
the 20 bp human intron of tRNAtyr gene with an equal length
of antisense sequence targeted at the 50 coding region of cyclin
D1, we constructed a set of plasmids for intracellular genera-
tion of antisense RNA. The antisense generated this way could
decrease cyclin D1 expression and thus inhibit the growth of
hepatoma cells, implying that pre-tRNA splicing could be
utilized in antisense technology.2. Materials and methods
2.1. Plasmids construction
A chemically synthesized DNA (Fig. 1A) was inserted into the KpnI/
XbaI sites of plasmid pUC18, yielding plasmid pUT. Two chemically
synthesized oligonucleotides Ccnd1a (50-TCGCAGCACAGG-
AGCTGGT-30) and Ccnd1b (50-GATCACCAGCTCCTGTGCTG-
CGA-30) were annealed, generating the ﬂanking sites of StuI and
BamHI. The resulting double-strand oligonucleotide was inserted intoation of European Biochemical Societies.
Fig. 1. Synthetic DNA sequences. Capital letters in bold indicate sequences from human tRNAtyr gene (A and B). The intron sequence of tRNAtyr
(plain capital letters in B) was substituted with a 10 bp oligonucleotide (plain capital letters in A), generating two restriction sites (StuI and BamHI) to
ease insertion of any antisenses, not limited to cyclin D1 as in this work. Letters in lower case represent the promoter sequence of U6 SnRNA gene
(A), which enhances the transcription eﬃciency of subsequent pre-tRNA. The U6 SnRNA promoter and the tRNA gene were spaced by two copies
of tet operator 2 sequence that serve as the binding sites for two molecules of the Tet repressor protein, so as to block the transcription of pre-tRNA
from both U6 SnRNA and tRNA promoters unless with tetracycline inducement.
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plasmid was used for generation of antisense RNA (50-
UCGCAGCACAGGAGCUGGUG-30) to human cyclin D1 (corre-
sponding to the 50 coding region) by pre-tRNA splicing. As a positive
control of splicing, native tRNAtyr gene was synthesized chemically
(Fig. 1B) and inserted into the SalI/XbaI sites of pUT and pUC18,
yielding pUT-tyr and pUC-tyr, respectively. To create stable cell lines
in which generation of antisense RNA can be regulated by tetracycline,
two plasmids, pTRUT-ccnd1 and pTRUT-tyr, were created by in-
serting the blunted KpnI/XbaI fragments of pUT-ccnd1 and pUT-tyr
into the blunted XhoI site of plasmid pcDNA6/TR (Invitrogen), re-
spectively.
2.2. In vitro transcription and splicing of pre-tRNAs using Hela nuclear
extracts
Hela nuclear extracts, containing all the components for transcrip-
tion and splicing of pre-tRNAs, were prepared according to Lee et al.
[12] and Dignam et al. [13] with slight modiﬁcation. In brief, Hela cells
of about 80% conﬂuence were trypsinized and washed twice with PBS.
The cells were suspended with one cell package volume of cold Buﬀer
A (10 mM HEPES–KOH, pH 7.9, at 4 C; 1.5 mM MgCl2; 10 mM
KCl; and 0.5 mM DTT) and were let swell on ice for 15 min. Then, the
cells were passed quickly through a Chinese standard 5# needle (inner
diameter 0.24 mm) for 10 times. Nucleus was collected by centrifu-
gation at 12 000 · g for 30 s, then resuspended with 2/3 original cell
package volume of cold Buﬀer C (20 mM HEPES–KOH, pH 7.9, at 4
C; 25% glycerol; 0.42 M NaCl; 1.5 mM MgCl2; 0.2 mM EDTA; 0.5
mM DTT; and 0.5 mM PMSF), and incubated on ice for 30 min with
shaking. After centrifugation at 12 000 · g for 2 min, the supernatants
were dialyzed against Buﬀer D (20 mMHEPES–KOH, pH 7.9, at 4 C;
20% glycerol; 0.1 M KCl; 0.2 mM EDTA; 0.5 mM DTT; and 0.5 mM
PMSF) at 4 C for 2 h. The extracts were kept in liquid nitrogen until
use. For in vitro transcription and splicing, 5 ll of Buﬀer D, 1 lg of
DNA template, 1.5 ll of 0.1 MMgCl2, 0.5 ll of RNasin, 7.5 ll of Hela
nuclear extract, 1 ll of 10 mM ATP/CTP/GTP each, 1 ll of 0.2 mM
UTP and 0.01 mCi of [a-32P]UTP were mixed well, and incubated at 30
C for 1 h. The samples were applied to 16% denatured polyacrylamide
gel electrophoresis (PAGE) with 8 M urea and directly applied to
autoradiography after electrophoresis.
2.3. Establishment of antisense generating H22 cell lines regulated by
tetracycline
Plasmids pTRUT-ccnd1 and pTRUT-tyr were transfected into hu-
man hepatoma H22 cells (provided by Dr. Chen of PLA General
Hospital, China) with Lipofectamine 2000 reagent (Invitrogen). Stableblasticidin resistant clones were screened out according to Invitrogen’s
instructions. Antisense RNA was induced for 24 h with 1lg/ml of
tetracycline added to the culture medium and then cyclin D1 expres-
sion was analyzed by Western blot.
2.4. Western blot analysis of cyclin D1 expression
The stably transfected H22 cells with or without antisense RNA
induction by tetracycline were collected by trypsinization, washed
twice with PBS, then resuspended in cold lysis buﬀer (50 mM Tris–
HCl, pH 8.0; 150 mM NaCl; 0.5% sodium deoxycholate; 0.1% SDS;
1% NP-40; and 0.5 mM PMSF) at exactly 107 cells/ml and incubated at
4 C for 30 min. After brief centrifugation, 20 ll of the supernatant was
applied to 12% reduced SDS–PAGE, then electrotransferred overnight
onto PVDF membrane (Millipore, Bedford, MA) at 40 V. The bands
were visualized by a primary anti-cyclin D1 monoclonal antibody
(cat# sc-8396, Santa Cruz Biotechnology) and an AP-conjugated goat-
anti-mouse IgG (Promega) as the secondary antibody. The membrane
was developed by Western Blue substrate (Promega).
2.5. Proliferation assay of H22 cells
Equal number of each stable blasticidin resistant cell line was seeded
into 48-well plate and cultured with or without 1 lg/ml tetracycline for
antisense RNA induction. After 2 days of induction, medium was
changed to 1 mg/ml MTT dissolved in serum-free medium. The cells
were incubated at 37 C for 4 h and then MTT solution was discarded.
The dye synthesized by active live cells was dissolved in 300 ll of
isopropanol and optical absorbance at 560 nm was measured.
2.6. Plasmid puriﬁcation for gene therapy
Escherichia coli DH5a containing plasmid pUT-ccnd1 was cultured
in a 10 L Bioﬂo V fermenter (NBS, New Jersey). Plasmid was extracted
from the bacteria by conventional alkaline lysis procedure and then
puriﬁed by strong anion exchange chromatography using Q-Sepharose
XL and SOURCE 15Q absorbents (Amersham Biosciences, Uppsala,
Sweden) according to the protocols provided by the manufacturer.
2.7. Animal experiments
Four-week-old female KM mice were inoculated s.c. in the right
thigh with 50 ll ascites of H22 hepatoma cells. When the tumor grew
to about 200 mm3 in size at day 5, 50 lg of puriﬁed plasmid pUT-
ccnd1 in 50 ll TE buﬀer or TE only control buﬀer was injected directly
into the tumors every other day. The length and width of tumor
nodules were measured with a caliper, and tumor volume was esti-
mated using the following formula:
Volume ¼ ðLengthWidthÞ3=2  p=6:
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immunohistochemistry
The tumor samples were ﬁxed and kept in 4% formaldehyde. Before
use, the samples were dehydrated with increasing concentration of
ethanol solution and xylene and embedded in paraﬃn. The samples
were sliced into about 4 lm sections and placed on clean glass slides.
The slides were baked at 80 C for 30 min to enhance the attachment of
sample sections onto the glass slides. For cyclin D1 detection, the
sections were hydrated, and probed with an anti-cyclin D1 monoclonal
antibody as mentioned above, and then a biotinized anti-mouse anti-
body and SABC complex (streptavidin–biotin-peroxidase, Boster
Biotech, Wuhan, China) in sequence. Labeled cells were visualized by
chromagen 30,30-diaminobenzidine, slightly conterstained with hema-
toxylin solution, and mounted with ClearmountTM (Zymed, South San
Francisco, CA). To detect apoptosis, the sections were labeled with
DIG at the end of fragmented DNA, which was characteristic of ap-
optosis, by labeling mixture (containing DIG-labeled dUTP, terminal
deoxynucleotidyl transferase and reaction buﬀer, Boster Biotech) at 37
C for 2 h, and then probed with a biotinized anti-DIG antibody and
SABC. Labeled cells were visualized, strongly counterstained and
mounted as mentioned above.3. Results
3.1. Eﬃcient small antisense RNA generation in vitro
Hela cell extract contains all the necessary components for
pre-tRNA transcription and splicing. The tRNA gene contains
a class three promoter within the gene itself. However, such a
promoter is relatively weaker than the promoter for U6
SnRNA, which transcribes about 400 000 copies of U6
SnRNA out of only a few copies of functional U6 gene per cell
[14]. In order to enhance pre-tRNA transcription for antisense
generation, the promoter of U6 SnRNA was put ahead of
tRNA gene. Fig. 2 shows that with U6 SnRNA promoter,
tRNA transcription in pUT-tyr and pUT-ccnd1 was consid-
erably higher than pUC-tyr, which contains only tRNAtyr
gene. It also proved that the 20 bp antisense RNA insert was
correctly spliced out as predicted.Fig. 2. In vitro transcription and splicing of pre-tRNA. With U6
SnRNA promoter, pre-tRNAs in pUT-tyr and pUT-ccnd1 were
transcribed more eﬃciently than pUC-tyr control. The 20 bp anti-cy-
clin D1 insert replacing the intron sequence of tRNAtyr gene was
correctly spliced out (pUT-ccnd1) as well as the native intron of
tRNAtyr gene (pUT-tyr).3.2. Cyclin D1 expression in H22 hepatoma cells decreased due
to antisense generation
It was attempted to create a stable cell line harboring anti-
sense RNA generating plasmid to test the eﬃcacy of cyclin D1
inhibition by antisense RNA. But H22 hepatoma cells grow
poorly in RPMI1640/10% FBS medium and transfection of
cyclin D1 antisense RNA generating plasmids into the cells
resulted in cell death. To overcome this problem, an inducible
strategy was designed. When transfected into H22 cells, plas-
mid pTRUT-ccnd1 will express a Tet repressor protein. The
repressor can bind to the two copies of tet operator 2 (TetO2)
sequence located between U6 SnRNA promoter and tRNA
gene, which had been integrated into the same plasmid, and
thus block tRNA transcription and subsequent splicing. Such
blocking can be released by tetracycline, which binds to Tet
repressor, changes its conformation and releases it from TetO2.
So addition of tetracycline into culture medium can induce
antisense RNA production. Plasmid pTRUT-ccnd1 and con-
trol plasmid pTRUT-tyr with native tRNAtyr gene were
transfected into H22 cells, and stable blasticidin-resistant
clones were screened out. Each of such stable clones and H22
negative control clone were cultured until 90% conﬂuence, and
then tetracycline was added to the medium to 1 lg/ml ﬁnal
concentration for induction of antisense RNA. Cyclin D1 ex-
pression was analyzed 24 h later. Fig. 3 shows that antisense
RNA against cyclin D1 generated this way inhibited cyclin D1
expression eﬃciently.
3.3. Antisense RNA slowed down proliferation of H22
hepatoma cells
Overexpression of Cyclin D1 is observed in many carcinoma
cells and is a key molecule for cell cycle progression. The ex-
pression of cyclin D1 is highly relevant to the proliferation
ability of mammalian cells. Cyclin D1 expression in H22 cells
was signiﬁcantly reduced by antisense RNA as proved above.
Such inhibition of cyclin D1 reduced the proliferation ability
of H22 cells, as shown in Fig. 4.Fig. 3. Western blot analysis of cyclin D1 expression. Stable blastici-
din-resistant H22 cell lines were created by transfection with pTRUT-
tyr or pTRUT-ccnd1. Both of the two cell lines together with
un-transfected H22 control cells were induced with tetracycline for 24
h. Then, cyclin D1 expression was analyzed by Western blot. b-Actin
expression was also analyzed as a control. In the ﬁgure, cyclin D1
expression was signiﬁcantly reduced by cyclin D1 antisense RNA.
Whereas intron of pre-tRNAtyr generated in the same way had no
eﬀect on cyclin D1 expression.
Fig. 5. Eﬀect of plasmid administration on tumor growth. Four days
after inoculation of H22 cells (Day 5), pUT-ccnd1 plasmid was injected
into the s.c. tumor xenografts at multiple sites until day 11 or day 15.
Tumor volumes were determined by bidimensional caliper measure-
ments and were presented as the mean tumor volume (n ¼ 8). The bars
stand for standard deviation. (*) Signiﬁcant (P < 0:05) volume diﬀer-
ence between plasmid treated tumors and TE treated control tumors.
ðmÞ Signiﬁcant (P < 0:05) diﬀerence between short-term plasmid
treated tumors (to day 11) and long-term treated tumors (to day 15).Fig. 4. Cell proliferation assay by MTT method. H22 cells were stained
by MTT. Proliferation of the cells was signiﬁcantly (P < 0:05) reduced
by the antisense RNA. The bars represent the standard deviations
calculated from three repeated experiments.
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antisense RNA
H22 hepatoma cells had been passaged in KM mouse for
many generations and became well adapted to KM mouse.
Ascites containing H22 cells was inoculated s.c. into the right
thigh of KM mouse at day 1, then tumor nodules grew rapidly
to about 200 mm3 at day 5. Afterwards, the mice were ran-Fig. 6. Immunohistochemical analysis of cyclin D1 expression and apoptosis i
Preformed tumor xenografts were harvested at day 17 after 6 times of plasmid
described in Section 2. (a) s.c. tumors treated with TE only; (b) s.c. tumorsdomly divided into three groups. Mice in group I were injected
with 50 ll of TE buﬀer directly into the tumor at multiple sites
every other day as a control. Mice in group II were injected
with 50 lg of pUT-ccnd1 in 50 ll TE buﬀer every other day
until day 11, then with TE buﬀer. Mice in group III were in-
jected continuously with 50 lg of pUT-cnnd1 in 50 ll TE
buﬀer every other day until day 15. Fig. 5 shows that the
growth of transplanted tumors was apparently inhibited by the
antisense RNA to cyclin D1 generated by tRNA splicing. Suchn s.c. tumor xenografts with and without plasmid pUT-ccnd1 injection.
injection. Cyclin D1 expression (A) and apoptosis (B) were analyzed as
treated with plasmid pUT-ccnd1.
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pUT-ccnd1 than application for only limited days.
3.5. Reduced cyclin D1 expression and apoptosis detected in
transplanted H22 hepatoma cells
Immunohistochemistry was performed to conﬁrm inhibition
of cyclin D1 expression by antisense RNA in preformed s.c.
tumors and to detect apoptosis caused by such inhibition of
cyclin D1 expression. Cyclin D1 was expressed in untreated
tumors in a homogeneous way (Fig. 6A(a)). However, in
plasmid treated tumors its expression was signiﬁcantly inhib-
ited (Fig. 6A(b)) at multiple sites, which may correspond to the
nearby regions of injection sites. Apoptosis was detected in
plasmid treated tumors (Fig. 6B(b)), but not in untreated tu-
mors (Fig. 6B(a)).4. Discussion
Ampliﬁcation or overexpression of cyclin D1 is frequently
observed in various human carcinomas. It occurs in about 60%
of breast cancers, 40% of colorectal cancers, 40% of squamous
carcinomas of the head and neck, 30% of hepatocellular car-
cinoma and 20% of prostate cancers [15,16]. Overexpression of
cyclin D1 in hepatocellular carcinoma was also described
elsewhere [17,18]. Cyclin D1 knockout mice exhibited resis-
tance to breast cancers induced by the neu and ras oncogene
[19]. Inhibition of cyclin D1 by antisense technology has been
described to lead to loss of tumorigenicity, increased chemo-
sensitivity or apoptosis in many cancer cells, including hepa-
tocellular [20], squamous [21,22], lung [23,24], pancreatic
[25,26], gastric [27], ovarian [28], colon [29] and esophageal [30]
carcinomas. Therefore, cyclin D1 was selected in this study as
the target of antisense RNA produced by pre-tRNA splicing to
test the feasibility of this system.
Antisense technology acts by interacting with speciﬁc target
sequences on mRNAs or their precursors through Watson–
Crick pairing, and inhibits translation or splicing of mRNAs,
thus inhibits expression of corresponding proteins. In contrast
to conventional pharmacological antagonists for inhibiting the
function of speciﬁc proteins, antisense technology is more at-
tractive due to its high speciﬁcity for their targets and its ease
in designing an antisense compound, which requires the in-
formation on only a small portion of nucleic acid sequence
encoding a given protein even without knowing the function of
that protein [31]. Antisense technology includes antisense oli-
godeoxynucleotides (ODN), antisense RNA and ribozymes.
Antisense ODNs have been most extensively studied and were
widely used in gene inhibition, especially in cancer therapy
[32,33]. Antisense ODNs have the advantages that they can be
synthesized commercially and easily standardized. However,
bioavailability and half-life in vivo have always been a chal-
lenge for ODNs due to poor permeability into the cells and
degradation by nucleases. Chemical modiﬁcations or analogs
can be used to improve bioavailability, but side eﬀects may
arise such as toxicity and poor speciﬁcity. In contrast, anti-
sense RNA transcribed intracellular from a vector would have
a longer duration of action after a single administration. In
addition, using tissue speciﬁc promoters can render antisense
RNA with tissue speciﬁcity. Most of the gene delivery vectors
for gene therapy can be used for antisense RNA administra-
tion. The only diﬀerence is changing the mRNA generatingcassette to an antisense RNA producing cassette [31]. In most
published papers, antisense RNA generation is conﬁned to
class II promoters [34]. These resulting antisense RNAs would
be 50 capped and 30 tailed, which may decrease the eﬃciency in
pairing with target mRNAs. In spite of the fact that natural
regulatory antisense RNAs are transcribed exclusively by
RNA polymerase II in human cells [35,36], their regulatory
eﬀects might not be fulﬁlled by tight pairing. Thus, RNA
polymerase III promoters may be preferable in antisense RNA
transcription. However, RNA polymerase III locates in the
nucleus, and it is highly probable that the antisense RNAs they
transcribed could not be exported eﬃciently into the cytosol,
because they might lack the special exporting structure as in
U6 SnRNA or 7SK RNA. So integrating the antisense RNA
into tRNA and utilizing its exporting machinery could be a
good choice. By replacing the anticodon loop of tRNApro with
an antisense sequence targeted at tat of HIV, Biasolo et al. [37]
showed that the 20 bp antisense RNA embedded in tRNApro
could resist HIV infection. In this study, however, we replaced
the intron, not the anticodon, of pre-tRNAtyr with an equal
length of anti-cyclin D1 sequence. The antisense RNA could
have been exported into the cytosol as eﬃciently as native pre-
tRNAtyr, and released into the cytosol without irrelevant 50
and 30 adjacent tRNA sequences to interfere with the base
pairing with corresponding target, and thus was believed to be
more eﬃcient than those described by Biasolo et al. [37] in
target gene inhibition.
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